EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma

KyoungSoo Lim, Aburough Abegesah, Chunling Fan, Jimmy Zhijian He, Xuyang Song, Cecil Chen, Alejandra Negro, Mallory Makowsky, Charu Gupta, Song Ren, Alex Phipps, Megan Gibbs und 1 weitere

The Journal of Clinical Pharmacology · 2023

DOI: 10.1002/jcph.2288 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von KyoungSoo Lim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel single‐dose regimen of 300 mg tremelimumab in combination with durvalumab (STRIDE) has demonstrated a favorable benefit–risk profile in the phase 1/2 Study 22 trial (in patients with unresectable hepatocellular carcinoma, uHCC) and in the phase 3 HIMALAYA study. The current analysis evaluated the population pharmacokinetics (PopPK) of tremelimumab and durvalumab, and the exposure–response (ER) relationship for efficacy and safety of STRIDE in patients with uHCC. Previous PopPK models for tremelimumab and durvalumab were updated using data from previous studies in various cancers combined with data from Study 22 and HIMALAYA. Typical population mean parameters and associated inter‐ and intra‐individual variability were assessed, as was the influence of covariates. Individual exposure metrics were derived from the individual empirical Bayes estimates as drivers for ER analysis related to efficacy and safety from HIMALAYA. The observed pharmacokinetics of tremelimumab in uHCC were well described by a 2‐compartment model with both linear and time‐dependent clearance. All identified covariates changed tremelimumab PK parameters by

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugModels, Biological

Stichwörter der Autor:innen

durvalumabexposure-response analysispopulation pharmacokineticstremelimumabunresectable hepatocellular carcinoma

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizeddurvalumabtremelimumab

Autor:innen und Institutionen

  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USA.
  • Clinical Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.

Förderung

  • AstraZeneca

Zitieren

APA

Lim, K., Abegesah, A., Fan, C., He, J. Z., Song, X., Chen, C., Negro, A., Makowsky, M., Gupta, C., Ren, S., Phipps, A., Gibbs, M., & Zhou, D. (2023). Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2288

Vancouver

Lim K, Abegesah A, Fan C, He JZ, Song X, Chen C, et al. Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2288

BibTeX
@article{Lim2023,
  author = {Lim, KyoungSoo and Abegesah, Aburough and Fan, Chunling and He, Jimmy Zhijian and Song, Xuyang and Chen, Cecil and Negro, Alejandra and Makowsky, Mallory and Gupta, Charu and Ren, Song and Phipps, Alex and Gibbs, Megan and Zhou, Diansong},
  title = {Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1002/jcph.2288}
}
Kostenlos starten →